Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
C M Rudin, J Holmlund, G F Fleming, et al.
Genes & Development
|
March 7, 1998
Overcoming cellular senescence in human cancer pathogenesis
T R Yeager, S DeVries, D F Jarrard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer
N J Vogelzang, S Mani, R L Schilsky, et al.
Cancer Research
|
April 18, 2001
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers
H L Kim, D J Vander Griend, X Yang, et al.
The Journal of Urology
|
August 1, 1996
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
M S Soloway, V Briggman, G A Carpinito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2023
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
A J Rosenberg, C-Y Liao, T Karrison, et al.
The Journal of Urology
|
October 1, 1996
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract
G A Carpinito, W M Stadler, J V Briggman, et al.
Clinical Pharmacology and Therapeutics
|
December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program
R P McKillip, B A Borden, P Galecki, et al.
Clinical Pharmacology and Therapeutics
|
April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing
P H O'Donnell, N Wadhwa, K Danahey, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2009
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L R Molife, G Attard, P C Fong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2001
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer
C M Rudin, J Holmlund, G F Fleming, et al.
Genes & Development
|
March 7, 1998
Overcoming cellular senescence in human cancer pathogenesis
T R Yeager, S DeVries, D F Jarrard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 14, 1998
Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer
N J Vogelzang, S Mani, R L Schilsky, et al.
Cancer Research
|
April 18, 2001
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers
H L Kim, D J Vander Griend, X Yang, et al.
The Journal of Urology
|
August 1, 1996
Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
M S Soloway, V Briggman, G A Carpinito, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 14, 2023
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
A J Rosenberg, C-Y Liao, T Karrison, et al.
The Journal of Urology
|
October 1, 1996
Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract
G A Carpinito, W M Stadler, J V Briggman, et al.
Clinical Pharmacology and Therapeutics
|
December 17, 2016
Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program
R P McKillip, B A Borden, P Galecki, et al.
Clinical Pharmacology and Therapeutics
|
April 12, 2017
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing
P H O'Donnell, N Wadhwa, K Danahey, et al.
Page
of 7